Enliven Therapeutics (ELVN) Gains from Investment Securities (2019 - 2026)

Enliven Therapeutics has disclosed Gains from Investment Securities across 8 years of filings, most recently posting $1.9 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $1.9 million, down 22.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 22.22% YoY), and the FY2025 annual result was $4.6 million, up 14.88% from the prior year.
• Gains from Investment Securities came in at $1.9 million for Q1 2026 at Enliven Therapeutics, down from $4.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $7.8 million in Q1 2024 to a low of $501839.0 in Q2 2022.
• The 5-year median for Gains from Investment Securities is $3.7 million (2025), against an average of $3.6 million.
• Across the five-year window, Gains from Investment Securities soared 814.69% in 2022 and sank 68.22% in 2025, its largest moves.
• Enliven Therapeutics' Gains from Investment Securities stood at $1.8 million in 2022, then soared by 224.42% to $6.0 million in 2023, then plunged by 33.28% to $4.0 million in 2024, then climbed by 14.88% to $4.6 million in 2025, then slumped by 57.97% to $1.9 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.9 million (Q1 2026), $4.6 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.